Valbiotis Logo

Valbiotis

Develops clinically tested, plant-based supplements for metabolic & cardiovascular health.

ALVAL | PA

Overview

Corporate Details

ISIN(s):
FR0013254851
LEI:
969500VP4JBJCF0MOP60
Country:
France
Address:
RUE PAUL VATINE, 17180 PERIGNY
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Valbiotis is a research and development company committed to scientific innovation for the prevention and management of metabolic and cardiovascular diseases. The company specializes in developing and marketing plant-based, clinically tested dietary supplements and active substances. Its core focus is on major health risk factors including prediabetes, dyslipidemia, arterial hypertension, and metabolic liver diseases. Leveraging its botanical expertise, Valbiotis creates multi-target active substances that act on multiple physiological pathways. The company's product portfolio, including the ValbiotisPRO® range, is distributed through pharmacies and is aimed at both healthcare professionals and consumers seeking scientifically validated natural health solutions.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-13 17:45
Declaration of Voting Results & Voting Rights Announcements
VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote …
French 150.8 KB
2025-10-13 17:45
Declaration of Voting Results & Voting Rights Announcements
VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote …
French 18.2 KB
2025-10-09 17:45
Earnings Release
VALBIOTIS SA: Valbiotis publishes its interim financial statements and confirms…
English 298.7 KB
2025-10-09 17:45
ISS
VALBIOTIS SA: Valbiotis publie ses comptes semestriels et confirme sa feuille d…
French 306.2 KB
2025-10-09 17:45
Earnings Release
VALBIOTIS SA: Valbiotis publishes its interim financial statements and confirms…
English 43.8 KB
2025-09-01 11:40
Declaration of Voting Results & Voting Rights Announcements
VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote …
French 18.2 KB
2025-08-11 17:30
Declaration of Voting Results & Voting Rights Announcements
VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote …
French 18.2 KB
2025-07-03 17:45
Declaration of Voting Results & Voting Rights Announcements
VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote …
French 165.4 KB
2025-07-03 17:45
Regulatory News Service
VALBIOTIS SA: Bilan semestriel du contrat de liquidité
French 359.3 KB
2025-07-03 17:45
Declaration of Voting Results & Voting Rights Announcements
VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote …
French 19.3 KB
2025-06-26 17:40
Share Issue/Capital Change
VALBIOTIS SA: Valbiotis announces the success of its €6.9 million rights issue …
English 470.3 KB
2025-06-26 17:40
Share Issue/Capital Change
VALBIOTIS SA: Valbiotis annonce le succès de son augmentation de capital de 6,9…
French 419.2 KB
2025-06-26 17:40
Share Issue/Capital Change
VALBIOTIS SA: Valbiotis announces the success of its 6.9 million rights issue e…
English 142.5 KB
2025-06-06 08:00
Share Issue/Capital Change
VALBIOTIS SA: Valbiotis announces the launch of a capital increase with maintai…
English 579.9 KB
2025-06-06 08:00
Share Issue/Capital Change
VALBIOTIS SA: Valbiotis annonce le lancement d’une augmentation de capital avec…
French 511.1 KB

Automate Your Workflow. Get a real-time feed of all Valbiotis filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Valbiotis via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-01-17 N/A Other Other 10,400 46,072.00 EUR

Peer Companies

Company Country Ticker View
Eisai Co., Ltd. Logo
A global, research-based pharmaceutical firm that develops and markets prescription and OTC drugs.
Japan 4523
Elicera Therapeutics AB Logo
Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.
Sweden ELIC
Ellen AB Logo
Develops research-based probiotic and prebiotic products for women's intimate health and pH balance.
Sweden ELN
Enlivex Therapeutics Ltd. Logo
Developing cell therapy to restore immune balance for inflammatory diseases like sepsis.
Israel ENLV
Enorama Pharma AB Logo
Develops & makes consumer nicotine products & medicated gums, offering private label solutions.
Sweden ERMA
Develops novel therapeutics and APIs for oncology, inflammation, and respiratory diseases.
South Korea 183490
Enzymatica AB Logo
Develops medical devices with patented enzyme technology to treat upper respiratory infections.
Sweden ENZY
Developing alopecia therapies, skin regeneration products, and preclinical CRO services.
South Korea 446440
EQL Pharma AB Logo
Develops and sells cost-efficient niche generic medicines for the Nordic healthcare market.
Sweden EQL
ERYTECH Pharma S.A. Logo
Developing phage therapies to combat antibiotic-resistant bacterial infections.
France ERYP

Talk to a Data Expert

Have a question? We'll get back to you promptly.